Lancet Commission Finds Four in Five Cancer Patients Globally Lack Essential Biomarker Testing

Four out of every five cancer patients worldwide who need molecular biomarker testing to guide their treatment are not receiving it. A new Lancet Oncology Commission report, published Friday, September 25, 2026, quantifies this massive equity gap, revealing that the benefits of precision oncology remain largely confined to high-income nations.[1][3]

The commission estimates that between seven and eight million people diagnosed with cancer globally require established, standard-of-care molecular testing each year. This testing examines a patient's biological material for specific genes and proteins, allowing oncologists to match tumors with targeted therapies and clinical trials.[1][3]

The rapid expansion of these technologies has created a "paradox of success," where the complexity and cost of precision care have outpaced its population-level benefits. Global spending on cancer medicines reached $252 billion in 2024, yet the infrastructure to deliver targeted treatments remains deeply fragmented. The report, unveiled at the 2026 World Cancer Congress in Hong Kong, brings together more than 50 commissioners from 21 countries and 48 partner organizations to map the current landscape.[1][3]

"Four out of five? We couldn't believe it when we saw that data coming out of our work," said Mark Lawler, co-chair of the commission and professor of digital health at Queen's University Belfast. "Precision oncology must be for all cancer patients, not just for the privileged few."[1]

The disparities extend deeply into the research and data ecosystems that underpin modern cancer care. According to the commission, only 2 percent of biomarker-based cancer clinical trials are conducted in low- and middle-income countries (LMICs). In contrast, high-income countries host nearly 81 percent of these trials.[3]

This geographic concentration means that clinical trial evidence and genomic datasets disproportionately represent populations of European ancestry. Oncologists in resource-limited settings are frequently left without locally relevant data to guide their clinical decisions, further widening the treatment gap.[2][3]

The real-world consequences of this testing deficit are stark. The researchers highlighted that approximately 314,000 women with ovarian cancer are eligible for BRCA gene testing annually. Nearly half of these women never receive the test, a shortfall driven almost entirely by low testing coverage in LMICs.[3]

"The expansion of precision oncology reflects major scientific achievements, which have helped to save and prolong many lives," noted Dr. Raffaella Casolino, co-chair of the commission. "However, it has also generated its own issues. New diagnostic systems, combined with rapidly changing evidence, financial burden and complex care needs, has meant that high-quality cancer care is increasingly difficult to deliver."

To address these structural barriers, the commission has proposed a phased implementation framework. This roadmap is designed to help different healthcare systems adopt genomic oncology advances at a sustainable pace, rather than attempting to deploy broad multi-gene sequencing immediately.[2][3]

The framework includes a system-readiness assessment tool, a workforce-competency guide, and principles for responsible data-sharing. By focusing on high-priority, cost-effective biomarkers first, the commission aims to break the cycle of unequal access and ensure that future genomic research reflects global diversity.[2][3]